Vasovistâ„¢ is an albumin-targeted
intravascular contrast agent. It is indicated for
contrast enhanced MR angiography (CE-MRA) for the visualization of abdominal or limb vessels in patients with suspected or known vascular disease. After IV injection, Vasovistâ„¢ binds reversibly to human albumin in plasma, which results in long-lasting increased
relaxivity. Imaging from 5 to 50 min is possible. A small unbound portion is, by glomerular filtration, eliminated by the kidneys.
AngioMARK® was the formerly trade name and
MS-325 the research name. Currently the
phase III clinical
trials are completed to determine its efficacy for peripheral vascular disease and coronary artery disease.
In the U.S., EPIX received an approvable letter from the U.S.
Food and Drug Administration (FDA) for Vasovistâ„¢ in January 2005. In 2009, Epix Pharmaceuticals has sold the U.S., Canadian and Australian rights for its
blood pool agent (now named
ABLAVARâ„¢), to
Lantheus Medical Imaging, Inc..
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based
contrast agents increase the risk for
nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m
2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or the
liver transplantation period.
See also
MRI Safety.
•
] and 21 definitions [
]
Further Reading:
Random Page
top
